what I really like about the article is
" Prima BioMed expects to enrol 1,000 patients in the study, which will be conducted across 100 sites in countries around the world. "
... 2 points
1. A large statiscal sample to validate results ... beyond questioning
2. A large trial base and volume of 'recruits ' ... that will enable Prime to get the ' mechanics ' and " manufacturing ' processes right ... unlike DNDN ... and be ready to roll big time when Commercialisation goes full swing ....
prima biomed: time to change leader, page-9
-
- There are more pages in this discussion • 26 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
40.5¢ |
Change
0.005(1.25%) |
Mkt cap ! $588.3M | |||
| Open | High | Low | Value | Volume |
| 40.0¢ | 40.5¢ | 39.8¢ | $2.431M | 6.045M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 6880 | 40.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 40.5¢ | 85353 | 3 |
View Market Depth
| Last trade - 16.10pm 12/09/2024 (20 minute delay) ? |
| IMM (ASX) Chart |